ACS Pharmacology & Translational Science is now included in PubMed Central. With this growing reach, the journal seeks to publish even more high-quality research under the editorial direction of ACS Chemical Neuroscience Editor-in-Chief Craig W. Lindsley. Professor Lindsley will further serve ACS Publications and the biomedical research community in the coming months as he provides […]
ACS Pharmacology & Translational Science is now included in PubMed Central. With this growing reach, the journal seeks to publish even more high-quality research under the editorial direction of ACS Chemical Neuroscience Editor-in-Chief Craig W. Lindsley.
Professor Lindsley will further serve ACS Publications and the biomedical research community in the coming months as he provides editorial leadership to ACS Pharmacology & Translational Science. Professor Lindsley will apply the scientific and editorial expertise he has used to make ACS Chemical Neuroscience a top-quality journal as he leads ACS Pharmacology & Translational Science until the journal’s next editor-in-chief is appointed later in 2020 for a term beginning January 1, 2021.
“ACS Pharmacology & Translational Science is an important and exciting component of the biological portfolio of ACS journals, filling an unmet need to disseminate the latest advances in basic and translational pharmacology across all therapeutic areas and molecular targets,” says Professor Lindsley.“ACS Pharmacology & Translational Science provides a new venue for academic researchers, as well as those in the pharmaceutical and biotech industry, to report new assays paradigms, new technologies, target-validation efforts, and human clinical trial monographs in one journal!”
Extensive Experience in Pharmacology, Translational Science, and Scholarly Publishing
Professor Lindsley has been working in medicinal chemistry, pharmacology, and translational drug discovery for nearly three decades and has served as the editor-in-chief of ACS Chemical Neurosciencesince its 2009 launch. He is the William K. Warren, Jr. Chair in Medicine, University Professor of biochemistry, chemistry, and pharmacology at Vanderbilt University in Nashville, Tennessee. He is also Center Co-Director and the Director of medicinal chemistry at the Warren Center for Neuroscience Drug Discovery (WCNDD).
“From my industry days at Eli Lilly and Merck to my current role in the WCNDD in the Department of Pharmacology at Vanderbilt, I understand and appreciate the value (and challenges) of basic and translational pharmacology,” says Professor Lindsley. “I think there is tremendous science in IND-enabling studies (DMPK and Tox), diverse biomarker strategies (including pharmacological challenge) and Phase I (SAD/MAD), Phase II, and Phase III trials.”
Professor Lindsley’s current research focuses on developing novel treatment strategies for schizophrenia, Parkinson’s disease, and other brain disorders. In 2019 he received the inaugural Scientific Achievement Award in Drug Discovery and Development from the American Society for Pharmacology and Experimental Therapeutics (ASPET) Division for Drug Discovery and Development.
Learn more: Read about the Craig Lindsley Research Group and find out which American rock band reads ACS Chemical Neuroscience in this ACS Axial post.
Call for Papers
Under Professor Lindsley’s leadership, ACS Pharmacology & Translational Science is eager to expand—publishing more of the high-quality Articles, Letters, Reviews, Perspectives, Viewpoints, and Drug Discovery Stories readers have enjoyed since its 2018 launch.
Professor Lindsley invites investigators working across the broad spectrum of pharmacology, biochemistry, and experimental medicine to submit manuscripts detailing their innovative, multidisciplinary research. He would also love to see more submissions from researchers working on clinical trials and those in the pharmaceutical and biotech industry.
“I invite you to submit your basic and translational pharmacology to the journal and expand your network within the biological portfolio of the ACS. I promise your work will be reviewed and published rapidly and that ACS will provide amazing exposure for your research, says Professor Lindsley.”
Professor Lindsley looks forward to receiving manuscripts covering a broad variety of topics, including, but not limited to:
- Epigenetics
- Immunology
- Renal disease
- Oncology
- Cardiovascular biology
- Metabolic diseases
- Central nervous system diseases
- Drug metabolism and pharmacokinetics
- Clinical trials
Free to Submit & Free to Publish
The reason: As a division of the American Chemical Society (ACS) and a nonprofit society publisher, ACS Publications is dedicated to advancing science and serving the needs of researchers.
Learn more about publishing with ACS Pharmacology & Translational Science and other ACS journals at the ACS Publishing Center.
The journal’s editors prioritize studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest, but they will consider all innovative research with articulated translational relevance.
If you have questions about the scope and/or about publishing in ACS Pharmacology & Translational Science, please contact Professor Lindsley at eic@ptsci.acs.org.
Read ACS Pharmacology & Translational Science
Institutional subscribers to All Publications, All Access, and token packages have access to all ACS Pharmacology & Translational Science articles and issues. If your institution is a subscriber, you can get access to the journal from any location using these remote access instructions.
Read the current issue of ACS Pharmacology & Translational Science.
